Red Book 2024: Report of the Committee on Infectious Diseases

Red Book 2024: Report of the Committee on Infectious Diseases

RED BK 2024 THIRTY-THIRD/E 33/

出版日期:
2024/05/19
7,875
訂單自國外空運,約14-21個工作天(不含例假日)到貨後依序出貨。為縮短等待,建議將此商品和其他商品分開下單。
查詢門市庫存

內容簡介

For more than 85 years health care professionals have "referred to the Red Book" for trustworthy guidance on pediatric infectious disease prevention, management, and control. The new 33rd edition continues this tradition of distinction with the latest clinical guidance on the manifestations, etiology, epidemiology, diagnosis, and treatment of more than 200 childhood infectious diseases. Find the latest information about vaccines, emerging novel diseases, diagnostic modalities, and treatment recommendations from the combined expertise of the CDC, the FDA, the NIH, and hundreds of physician contributors. Red Book guidance spans far beyond the pediatric practice to include family medicine, emergency medicine, public health, school health, and other medical specialties. New in the 2024 Red Book All chapters were assessed for relevance in the dynamic environment that is the practice of pediatric medicine today, and every chapter has been modified since the last edition. The chapter Discussing Vaccines With Patients and Parents has been significantly revised. Two new chapters on COVID-19 and Mpox have been added. Greatly expanded tables, figures, and algorithms enable quick access to essential information. The System-Based Treatment Table has been moved to the beginning of the book and has been reordered so that the grouped recommendations by body system are more easily and quickly accessed. Standardized approaches to disease prevention through immunizations, antimicrobial prophylaxis, and infection-control practices have been updated throughout the Red Book. Reference to evidence-based policy recommendations have been updated throughout the Red Book. Appropriate chapters throughout the Red Book have been updated to be consistent with 2024 AAP and CDC vaccine recommendations, CDC recommendations for immunization of health care personnel, and drug recommendations from 2024 Nelson's Pediatric Antimicrobial Therapy. The Breastfeeding and Human Milk chapter was updated to align with information in the 2022 AAP policy statement on breastfeeding. The listing of Codes for Commonly Administered Pediatric Vaccines, Toxoids, and Immune Globulins has been expanded.
展開看更多

作者介紹

David W. Kimberlin, MD, FAAP is the Editor of the 2021 AAP Report of the Committee on Infectious Diseases (Red Book). He also was Editor of the 2015 and 2018 editions and was an Associate Editor of the 2012 and 2009 editions and served on the AAP Committee on Infectious Diseases from 2005- 2011. Dr. Kimberlin is the Sergio Stagno, MD. Endowed Chair in Infectious Diseases, Professor and Co-Division Director, Vice Chair for Clinical and Translational Research. His clinical and research interests include pediatric infectious diseases, antiviral therapeutics in rare diseases with a large unmet medical need, including neonatal herpes simplex virus (HSV) infections, congenital cytomegalovirus (CMV) disease, congenital Zika infection, neonatal and infantile influenza infection, and neonatal enteroviral sepsis syndrome. Dr. Ritu Banerjee is Professor in the Division of Pediatric Infectious Diseases at Vanderbilt University Medical Center. She is the Director of the Pediatric Antimicrobial Stewardship Program and Interim Director of Pediatric Infectious Diseases at Vanderbilt. She received her MD and Ph.D degrees from Washington University in St. Louis and then completed Pediatrics residency and Pediatric Infectious Disease fellowship at the University of California, San Francisco.She is a member of many national committees through the Pediatric Infectious Diseases Society, the American Academy of Pediatrics, the Infectious Diseases Society of America, and the Antibacterial Resistance Leadership Group. Dr. Banerjee conducts clinical research about antibiotic stewardship, implementation and outcomes of rapid blood culture diagnostics, and enhanced detection of carbapenem-resistant organisms. Elizabeth D. Barnett, MD, FAAP is an Associate Editor of the 2021 Red Book and was a member of the Committee on Infectious Diseases from 2014 - 2020. Dr. Elizabeth Barnett is Professor of Pediatrics at Boston University School of Medicine and Chief, Section of Pediatric Infectious Diseases in the Department of Pediatrics at Boston Medical Center. She leads the Refugee Health Assessment Program and the Pediatric Travel Clinic. Her clinical and research interests include vaccines and vaccine safety, refugee and immigrant medicine, travel medicine, and general pediatric infectious diseases. Ruth Lynfield, MD, FAAP is an Associate Editor of the 2021 Red Book and has been a member of the Committee on Infectious Diseases since 2015. Dr. Lynfield is the State Epidemiologist and Medical Director at the Minnesota Department of Health. She leads Minnesota's component of CDC's Emerging Infections Program Active Bacterial Core Surveillance System, influenza projects, and healthcare-associated infections projects. She is also Adjunct Professor of Medicine, and Epidemiology and Community Health at the University of Minnesota. Her clinical and research interests include pediatric infectious diseases, antimicrobial resistance and antimicrobial stewardship, emerging infections, prevention and control of infectious diseases, and outbreak response. Mark Sawyer, MD, FAAP is an Associate Editor of the 2021 Red Book and served on the Committee on Infectious Diseases from 2013- 2019. Dr. Sawyer is an infectious disease specialist at Rady Children's Hospital and a professor of clinical pediatrics at UC San Diego. Additionally, Dr. Sawyer is vice chair for education in the UC San Diego Department of Pediatrics and the program director for the UC San Diego/Rady Children's Pediatric Residency Program and the medical director of the UC San Diego Immunization Partnership. His clinical and research interests include pediatric infectious diseases, medical education, training, and working with public health on the delivery of vaccines and national vaccine policy.

規格

誠品貨碼 /
ISBN13 / 9781610027342
ISBN10 /
EAN貨碼 / 9781610027342
裝訂 / P:平裝
頁數 / 1100
語言 / 3:英文
級別 / N:無
尺寸 / 22.9X15.3X5.5CM

退貨說明

退貨須知:

  1. 依照消費者保護法的規定,您享有商品貨到次日起七天猶豫期(含例假日)的權益(請注意!猶豫期非試用期),辦理退貨之商品必須是全新狀態(不得有刮傷、破損、受潮)且需完整(包含全部商品、配件、原廠內外包裝、贈品及所有附隨文件或資料的完整性等)。
  2. 請您以送貨廠商使用之包裝紙箱將退貨商品包裝妥當,若原紙箱已遺失,請另使用其他紙箱包覆於商品原廠包裝之外,切勿直接於原廠包裝上黏貼紙張或書寫文字。若原廠包裝損毀將可能被認定為已逾越檢查商品之必要程度,本公司得依毀損程度扣除回復原狀必要費用(整新費)後退費;請您先確認商品正確、外觀可接受,再行拆封,以免影響您的權利;若為產品瑕疵,本公司接受退貨。

依「通訊交易解除權合理例外情事適用準則」,下列商品不適用七日猶豫期,除產品本身有瑕疵外,不接受退貨:

  1. 易於腐敗、保存期限較短或解約時即將逾期。(如:生鮮蔬果、乳製品、冷凍冷藏食材、蛋糕)
  2. 依消費者要求所為之客製化給付。(如:客製印章、鋼筆刻字)
  3. 報紙、期刊或雜誌。
  4. 經消費者拆封之影音商品或電腦軟體。
  5. 非以有形媒介提供之數位內容或一經提供即為完成之線上服務,經消費者事先同意始提供。(如:電子書)
  6. 已拆封之個人衛生用品。(如:內衣褲、襪類、褲襪、刮鬍刀、除毛刀等貼身用品)
  7. 國際航空客運服務。

若您退貨時有下列情形,可能被認定已逾越檢查商品之必要程度而須負擔為回復原狀必要費用(整新費),或影響您的退貨權利,請您在拆封前決定是否要退貨:

  1. 以數位或電磁紀錄形式儲存或著作權相關之商品(包含但不限於CD、VCD、DVD、電腦軟體等) 包裝已拆封者(除運送用之包裝以外)。
  2. 耗材(包含但不限於墨水匣、碳粉匣、紙張、筆類墨水、清潔劑補充包等)之商品包裝已拆封者(除運送用之包裝以外)。
  3. 衣飾鞋類/寢具/織品(包含但不限於衣褲、鞋子、襪子、泳裝、床單、被套、填充玩具)或之商品缺件(含購買商品、附件、內外包裝、贈品等)或經剪標或下水或商品有不可回復之髒污或磨損痕跡。
  4. 食品、美容/保養用品、內衣褲等消耗性或個人衛生用品、商品銷售頁面上特別載明之商品已拆封者(除運送用之包裝外一切包裝、包括但不限於瓶蓋、封口、封膜等接觸商品內容之包裝部分)或已非全新狀態(外觀有刮傷、破損、受潮等)與包裝不完整(缺少商品、附件、原廠外盒、保護袋、配件紙箱、保麗龍、隨貨文件、贈品等)。
  5. 家電、3C、畫作、電子閱讀器等商品,除商品本身有瑕疵外,退回之商品已拆封(除運送用之包裝外一切包裝、包括但不限於封膜等接觸商品內容之包裝部分、移除封條、拆除吊牌、拆除貼膠或標籤等情形)或已非全新狀態(外觀有刮傷、破損、受潮等)與包裝不完整(缺少商品、附件、原廠外盒、保護袋、配件紙箱、保麗龍、隨貨文件、贈品等)。
  6. 退貨程序請參閱【客服專區→常見問題→誠品線上退貨退款】之說明。
付款/配送